Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2021-07-06

FDA Approved: BUPIVACAINE HYDROCHLORIDE — Supplemental Application (Hospira, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Bupivacaine hydrochloride (Hospira, Inc.), indicating a change to the approved product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bupivacaine hydrochloride (bupivacaine hydrochloride)

Snippet

SUPPL AP for BUPIVACAINE HYDROCHLORIDE (BUPIVACAINE HYDROCHLORIDE)